 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...180181182183184185186187188189190...235236» |
- | Farydak (panobinostat) / Secura Bio
Trial completion date, Trial primary completion date, Combination therapy: Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 20, 2018
P1, N=36, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- || Enrollment change, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Jun 20, 2018
P1, N=340, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 N=240 --> 340
- ||||| New P2 trial, Metastases: QUILT-3.088: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) - Jun 19, 2018
P2, N=1064, Not yet recruiting, Sponsor: NantKwest, Inc.
- |||| Opdivo (nivolumab) / BMS
New P2 trial: Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer (clinicaltrials.gov) - Jun 19, 2018
P2, N=170, Not yet recruiting, Sponsor: Massachusetts General Hospital
- ||||| New P1/2 trial, Metastases: QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) - Jun 19, 2018
P1/2, N=382, Not yet recruiting, Sponsor: NantKwest, Inc.
- | Trial completion, Surgery: Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - Jun 19, 2018
P=N/A, N=23, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=240 --> 340 Active, not recruiting --> Completed
- || navicixizumab (OMP-305B83) / Feng Biosci
Enrollment change, Metastases: A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 19, 2018
P1b, N=60, Recruiting, Sponsor: OncoMed Pharmaceuticals, Inc.
Active, not recruiting --> Completed N=30 --> 60
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Phase classification, Metastases: Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study) (clinicaltrials.gov) - Jun 19, 2018
P3, N=147, Recruiting, Sponsor: Fudan University
N=30 --> 60 Phase classification: P2 --> P3
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial completion: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Jun 15, 2018
P3, N=1895, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P2 --> P3 Active, not recruiting --> Completed
- |||| andecaliximab (GS-5745) / Gilead
Trial primary completion date, Metastases: GAMMA-1: Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jun 14, 2018
P3, N=432, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Trial primary completion date: Jan 2019 --> Jul 2018
- |||||||||| Kinaction (masitinib) / AB Science
New P2/3 trial, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 13, 2018
P2/3, N=295, Recruiting, Sponsor: AB Science
- | Avastin (bevacizumab) / Roche
Trial completion, Trial completion date, Metastases: PRODIGE 9: Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 13, 2018
P3, N=492, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Trial primary completion date: Jan 2019 --> Jul 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jan 2018
- | NN1213 / Novo Nordisk
Trial suspension, Surgery: A021501: Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - Jun 12, 2018
P2, N=134, Suspended, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jan 2018 Recruiting --> Suspended
- ||||| New P2 trial: QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (clinicaltrials.gov) - Jun 11, 2018
P2, N=376, Not yet recruiting, Sponsor: NantKwest, Inc.
- |||| Bavencio (avelumab) / EMD Serono
Trial primary completion date, Metastases: Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) (clinicaltrials.gov) - Jun 11, 2018
P3, N=499, Active, not recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Recruiting --> Suspended Trial primary completion date: Mar 2019 --> Nov 2019
- futuximab/modotuximab (S95026) / Servier
Trial completion date, Trial termination, Combination therapy, Metastases: Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Jun 8, 2018
P1b/2a, N=10, Terminated, Sponsor: Symphogen A/S
Trial primary completion date: Mar 2019 --> Nov 2019 Trial completion date: Dec 2018 --> May 2018 | Active, not recruiting --> Terminated; Discontinued development of Sym004 in combination with FOLFIRI
- || monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Jun 8, 2018
P1, N=262, Recruiting, Sponsor: MedImmune LLC
Trial completion date: Dec 2018 --> May 2018 | Active, not recruiting --> Terminated; Discontinued development of Sym004 in combination with FOLFIRI Trial primary completion date: Jan 2022 --> Feb 2020
- | ipatasertib (RG7440) / Roche
Trial completion date, Combination therapy, Metastases: A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jun 7, 2018
P2, N=154, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Jan 2022 --> Feb 2020 Trial completion date: Jun 2018 --> Jun 2019
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: Organ Preservation in Early Rectal Cancer Patients (clinicaltrials.gov) - Jun 6, 2018
P2, N=19, Not yet recruiting, Sponsor: Fox Chase Cancer Center
- | Trial completion date, Trial primary completion date, Combination therapy: Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Jun 6, 2018
P1, N=38, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Jun 2018 --> Jun 2019 Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Enrollment open: PENCOLA: Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime (clinicaltrials.gov) - Jun 6, 2018
P=N/A, N=30, Recruiting, Sponsor: Lund University Hospital
Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 Not yet recruiting --> Recruiting
- |||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
New P2 trial: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Jun 5, 2018
P2, N=78, Not yet recruiting, Sponsor: Darren Carpizo, MD
- | leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Clinical, Journal: Management of Patients with Acute Methotrexate Nephrotoxicity with High-Dose Leucovorin. (Pubmed Central) - Jun 5, 2018
There were no deaths directly attributed to complications related to high-dose methotrexate therapy. Glucarpidase, an expensive drug, may not be necessary for a significant number of patients.
- || AZD0156 / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, PARP Biomarker, Metastases: AToM: Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (clinicaltrials.gov) - Jun 4, 2018
P1, N=225, Recruiting, Sponsor: AstraZeneca
Glucarpidase, an expensive drug, may not be necessary for a significant number of patients. Trial completion date: Mar 2020 --> Oct 2020 | Trial primary completion date: Mar 2020 --> Oct 2020
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment change, Trial completion date, Trial primary completion date, Metastases: MM-398-07-02-03: Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 4, 2018
P1/2, N=54, Recruiting, Sponsor: Ipsen
Trial completion date: Mar 2020 --> Oct 2020 | Trial primary completion date: Mar 2020 --> Oct 2020 N=204 --> 54 | Trial completion date: Apr 2022 --> Oct 2019 | Trial primary completion date: Oct 2019 --> Feb 2019
- | Affecizx (hPV19) / Stainwei Biotech
New P1 trial, Combination therapy, Metastases: A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors (clinicaltrials.gov) - Jun 3, 2018
P1, N=18, Not yet recruiting, Sponsor: SuZhou Stainwei Biotech Inc.
- | New trial: PENCOLA: Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime (clinicaltrials.gov) - Jun 3, 2018
P=N/A, N=30, Not yet recruiting, Sponsor: Lund University Hospital
- | Enrollment open: GABLE: Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers (clinicaltrials.gov) - Jun 2, 2018
P1, N=40, Recruiting, Sponsor: Brandon G. Smaglo
N=204 --> 54 | Trial completion date: Apr 2022 --> Oct 2019 | Trial primary completion date: Oct 2019 --> Feb 2019 Not yet recruiting --> Recruiting
- ||| Vyloy (zolbetuximab-clzb) / Astellas
Biomarker, Enrollment open, Monotherapy, PD(L)-1 Biomarker: ILUSTRO: A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer (clinicaltrials.gov) - Jun 2, 2018
P2, N=102, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Vectibix (panitumumab) / Amgen
Trial completion: PULSE: Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 2, 2018
P2, N=78, Completed, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: POWERRANGER: Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (clinicaltrials.gov) - Jun 1, 2018
P2/3, N=60, Recruiting, Sponsor: Dr. Gordon Buduhan
Active, not recruiting --> Completed Trial completion date: Feb 2019 --> Apr 2021 | Trial primary completion date: Feb 2018 --> Apr 2020
- | Trial completion date, Surgery: Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") (clinicaltrials.gov) - Jun 1, 2018
P2, N=130, Active, not recruiting, Sponsor: Medical College of Wisconsin
Trial completion date: Feb 2019 --> Apr 2021 | Trial primary completion date: Feb 2018 --> Apr 2020 Trial completion date: Dec 2018 --> Dec 2021
- | Avastin (bevacizumab) / Roche
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Surgery: Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (clinicaltrials.gov) - Jun 1, 2018
P2, N=17, Active, not recruiting, Sponsor: University of Southern California
Trial completion date: Dec 2018 --> Dec 2021 Recruiting --> Active, not recruiting | N=43 --> 17 | Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2018 --> Aug 2019
- || dilpacimab (ABT-165) / AbbVie
Trial completion date, Trial primary completion date, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Jun 1, 2018
P1, N=80, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting | N=43 --> 17 | Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2018 --> Aug 2019 Trial completion date: Jun 2018 --> Jan 2020 | Trial primary completion date: Apr 2018 --> Jan 2020
- |||||| Vyloy (zolbetuximab-clzb) / Astellas
Enrollment open, Metastases: Spotlight: A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov) - May 31, 2018
P3, N=550, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Trial completion date: Jun 2018 --> Jan 2020 | Trial primary completion date: Apr 2018 --> Jan 2020 Not yet recruiting --> Recruiting
- | Biomarker, New trial, Metastases: Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (clinicaltrials.gov) - May 27, 2018
P=N/A, N=264, Completed, Sponsor: Fudan University
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial, Metastases: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (clinicaltrials.gov) - May 21, 2018
P2, N=196, Not yet recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
- ||| petosemtamab (MCLA-158) / Merus
New P1 trial, Metastases: MCLA-158-CL01: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 18, 2018
P1, N=120, Recruiting, Sponsor: Merus N.V.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Metastases: LOGIC: FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma (clinicaltrials.gov) - May 18, 2018
P2, N=36, Not yet recruiting, Sponsor: University of Saskatchewan
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Metastases: NIFTY: Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer (clinicaltrials.gov) - May 16, 2018
P2, N=174, Not yet recruiting, Sponsor: Changhoon Yoo
- | napabucasin (BBI608) / Sumitomo Pharma
New P3 trial, Combination therapy, Metastases: A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 11, 2018
P3, N=668, Recruiting, Sponsor: 1Globe Biomedical Co., Ltd.
- || Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: NCI-2018-00737: Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 8, 2018
P2, N=44, Recruiting, Sponsor: M.D. Anderson Cancer Center
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Combination therapy, Metastases: TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC (clinicaltrials.gov) - May 8, 2018
P2, N=41, Completed, Sponsor: TTY Biopharm
- | Avastin (bevacizumab) / Roche, NN1213 / Novo Nordisk
Enrollment closed: Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis (clinicaltrials.gov) - May 4, 2018
P2, N=50, Active, not recruiting, Sponsor: University of California, San Diego
Not yet recruiting --> Recruiting Terminated --> Active, not recruiting
- | veliparib (ABT-888) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD)
Trial suspension, PARP Biomarker, Metastases: NRG-GI002: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (clinicaltrials.gov) - May 4, 2018
P2, N=174, Suspended, Sponsor: National Cancer Institute (NCI)
Terminated --> Active, not recruiting Recruiting --> Suspended
- |||| epacadostat (INCB024360) / Incyte
New P1/2 trial: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - May 3, 2018
P1/2, N=57, Not yet recruiting, Sponsor: Washington University School of Medicine
- | New P1 trial: GABLE: Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers (clinicaltrials.gov) - May 3, 2018
P1, N=40, Not yet recruiting, Sponsor: Brandon G. Smaglo
- | 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 3, 2018
P2, N=50, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Suspended Trial completion date: Mar 2018 --> Nov 2018
- | Trial completion date, Trial primary completion date: PROMENADE: Proactive Management of Endoperitoneal Spread in Colonic Cancer (clinicaltrials.gov) - May 3, 2018
P3, N=140, Not yet recruiting, Sponsor: University of Roma La Sapienza
Trial completion date: Mar 2018 --> Nov 2018 Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Sep 2022 --> Mar 2023
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. (clinicaltrials.gov) - May 2, 2018
P2, N=32, Not yet recruiting, Sponsor: University of Saskatchewan
Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Sep 2022 --> Mar 2023 Trial completion date: Dec 2022 --> Aug 2021 | Initiation date: Mar 2018 --> Sep 2018 | Trial primary completion date: Dec 2020 --> Aug 2021